Reboxetine

Reboxetine
	(R,R)-(–)-reboxetine (top),; (S,S)-(+)-reboxetine (bottom)
Clinical data
Trade names	Edronax, others
Pregnancy; category	AU: B1;
Routes of; administration	By mouth (tablets)
ATC code	N06AX18 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); UK: POM (Prescription only); US: Not approved;
Pharmacokinetic data
Bioavailability	≥94%
Protein binding	97–98%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	12–12.5 hours
Excretion	Urine (78%; 9–10% unchanged)
Identifiers
	IUPAC name rel-(2R)-2-[(R)-(2-Ethoxyphenoxy)(phenyl)methyl]morpholine;
CAS Number	71620-89-8 ; Mesylate: 98769-84-7 ;
PubChem CID	127151;
DrugBank	DB00234 ;
ChemSpider	112870 ;
UNII	947S0YZ36I; Mesylate: L94J81YNNY ;
KEGG	D08472 ;
ChEMBL	ChEMBL383921 ;
Chemical and physical data
Formula	C19H23NO3
Molar mass	313.397 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemate
	SMILES CCOC1=C(C=CC=C1)O[C@@H]([C@@H]2OCCNC2)C3=CC=CC=C3;
	InChI InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1 ; Key:CBQGYUDMJHNJBX-RTBURBONSA-N ;
	(what is this?) (verify)

Reboxetine, sold under the brand name Edronax among others, is a drug of the norepinephrine reuptake inhibitor (NRI) class, marketed as an antidepressant by Pfizer for use in the treatment of major depression, although it has also been used off-label for panic disorder and attention deficit hyperactivity disorder (ADHD). It is approved for use in many countries worldwide, but has not been approved for use in the United States. Although its effectiveness as an antidepressant has been challenged in multiple published reports, its popularity has continued to increase.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.